Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Clin Cancer Res. 2018 Feb 20;24(10):2417–2429. doi: 10.1158/1078-0432.CCR-17-1556

Fig. 1.

Fig. 1

C-82 induces apoptosis, suppresses growth, and inhibits β-catenin targets in AML cells and stem/progenitor cells. (A) AML cell lines were treated with C-82 for 48 h. Apoptosis was measured by flow cytometry. Viable cell count was assessed by Trypan blue exclusion method. Cell cycle status was determined by flow cytometry. (B) AML patient and normal BM (NBM) samples were treated with C-82. Apoptosis in bulk and CD34+CD38− AML (72 h) and normal CD34+ (48 h) cells was measured by flow cytometry. (C) Molm13 and OCI-AML3 cells were treated for 24, 48, or 72 h and AML patient samples for 72 h with C-82. Survivin, CD44, and c-Myc expressions were determined by western blot or flow cytometry. For Molm13 and OCI-AML3 cells, the top panel shows a representative western blot and the lower panel the quantitative western blots of three independent experiments. *, P<0.05; **, P<0.01.